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Background: The detection of serum tumor marker becomes a common method for screening tumors. However,
this method has not been widely used for routine gastric cancer screening. In this study we aimed to determine
whether the combined use of tumor markers may increase the sensitivity for the diagnosis of gastric cancer.
Methods: Serum AFP, CEA, CA125 and CA19-9 levels were measured in 149 patients with gastric cancer, 111
patients with benign gastric diseases and 124 healthy people, who visited the First Affiliated Hospital of Nanchang
University from May 2011 to May 2012. Statistical analysis including receiver operating characteristic (ROC) curve,
the area under the curve (AUC), and logistic regression analysis was performed to evaluate the diagnostic value of
these markers on gastric cancer.
Results: Serum levels of CEA, CA125, and CA19-9 in gastric cancer group were higher than that in the benign
gastric disease group and the healthy control group (P <0.005). The sensitivity of AFP, CEA, CA125 and CA19-9 in
the diagnosis of gastric cancer was 4.7-20.8% individually, and increased to 40.3% in combination. By using optimal
cut-off value, the sensitivity of CEA, CA125, and CA19-9 for the diagnosis of gastric cancer was improved. Especially,
the sensitivity of CEA increased to 58.4% and the sensitivity of combined use of four markers increased to 69.1%.
The age and gender had no effects on the diagnostic value of these markers.
Conclusions: The determination and application of optimal cut-off values based on ROC curve and logistic
regression analysis could improve the diagnosis of gastric cancer based on common tumor markers.
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It is difficult to differentiate the syndromes of gastric
cancer and benign gastric diseases. Up to now, few
effective biomarkers for gastric cancer have been applied
in the clinic for the diagnosis of gastric cancer [1]. Cur-
rently, the diagnosis of gastric cancer mainly depends on
invasive examination such as gastroscopy and biopsy.
The detection of serum tumor marker is simple and easy
and becomes a common clinical method for screening
tumor. Tumor markers such as alpha fetoprotein (AFP),
carcinoembryonic antigen (CEA), cancer antigen 125
(CA125) and cancer antigen 19–9 (CA19-9) have been* Correspondence: yfyzkh@sina.com
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reproduction in any medium, provided the orwidely used for the diagnosis of different types of
cancers such as liver cancer, colorectal cancer and
pancreatic cancer. However, when these markers are
used individually for the diagnosis of gastric cancer,
inconsistent results have been obtained [2-6].
A recent study reported that the use of a combination
of Ki-67, Galectin-3, and PTTG can distinguish the
benign and malignant thyroid tumor [7]. Therefore, we
hypothesized that the combined use of tumor markers
may avoid the inconsistence and increase the sensitivity
for the diagnosis of gastric cancer. In this study we
detected the serum levels of tumor markers AFP, CEA,
CAl25 and CAl9-9 in 149 patients with gastric cancer,
111 patients with benign gastric diseases and 124 healthy
people. Next we performed statistical analysis to com-
pare the diagnostic value of these markers for gastricThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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optimal cut-off values of these markers could increase
the sensitivity for the diagnosis of gastric cancer.Methods
Study subjects
Total 384 subjects were enrolled in this study who
visited the First Affiliated Hospital of Nanchang University
from May 2011 to May 2012, including patients with
gastric cancer and benign gastric diseases, and healthy
people who underwent physical examination. There were
149 patients in gastric cancer group (115 men, 34 women,
age range 28 to 90 years old, average 59.1 years old).
Among them, 30 patients had early gastric cancer and 119
patients had advanced gastric cancer. 71 patients had
poorly differentiated adenocarcinoma, 72 patients had
moderately differentiated adenocarcinoma, and 6 patients
had highly differentiated adenocarcinoma. 70 patients had
gastric antrum carcinoma, 61 patients had gastric body
cancer, 13 patients had gastric cardia - bottom cancer, and
5 patients had multiple site cancer (more than two sites).
There were 111 patients in benign gastric disease group
(76 men, 35 women, age range 25 to 86 years old, average
52.9 years old). Among them, 24 patients had gastric ulcer,
53 patients had duodenal ulcer, 12 patients had complex
ulcer, 17 patients had non-atrophic gastritis, and 5
patients had atrophic gastritis. 124 healthy people were
included in the control group (72 men, 52 women, age
range 37 to 83 years old, average 53.0 years old). Patients
with gastric cancer and benign gastric diseases were
diagnosed by endoscopy and confirmed by biopsy.
This study was performed in compliance with the
Helsinki Declaration and according to a protocol ap-
proved by the Medical Ethics Committee of Nanchang
University. All patients were informed about the study
and gave their consent.Table 1 Serum levels of AFP CEA, CA125 and CA19-9 in the st
Gastric cancer(n=149) Benign gast
Age (Year) 59.1±11.5 52.9±17.4
Gender (Male/Female) 115/34 76/35
AFP (ng/mL) 3.8±16.8 3.3±18.6
CEA (ng/mL) 10.5±27.8 1.9±2.8
CA125 (U/mL) 20.1±32.7 11.6±17.5
CA19-9 (U/mL) 22.8±39.1 11.4±18.7
AFP Positive cases (%) 7 (4.7) 1 (0.9)
CEA Positive cases (%) 26 (17.4) 2 (1.8)
CA125 Positive cases (%) 21(14.1) 7 (6.3)
CA19-9 Positive cases (%) 31(20.8) 9 (8.1)
Combination Positive Cases (%) 60 (40.3) 14 (12.6)Serum tumor marker detection
Serum AFP, CEA, CA125 and CA19-9 levels were
detected by using Roche electrochemiluminescence
instrument at Department of Nuclear Medicine of the
First Affiliated Hospital of Nanchang University. The
normal reference values were as follows: AFP≤7 ng/mL,
CEA≤6.5 ng/mL, CAl25≤ 35 U/mL, CAl9-9≤27 U/mL.
Statistical analysis
The data were expressed as mean ± standard deviation.
The area under curve (AUC) of receiver operating
characteristic (ROC) curve was used to evaluate the
diagnostic value of serum tumor markers. Multivariate
logistic regression analysis was used to establish the
diagnostic mathematical model. On the basis of this
model, the prediction value was calculated followed by
ROC curve analysis. The statistical analysis was
performed using SPSS17.0 statistical software (SPSS Inc.,
Chicago, IL, USA).
Results
The serum levels of CEA, CA125, CA19-9 and AFP in the
study subjects
The demographic data such as age and gender and the
test results of four serum tumor markers in gastric
cancer group, benign gastric disease group and healthy
control group were shown in Table 1. The average
serum level and the positive rate of AFP, CEA, CA125
and CA19-9 in gastric cancer group were higher than
that in the benign gastric disease group and the healthy
control group.
Positive rates of serum tumor markers in gastric cancer of
different clinicopathological features
According to the stage, location and histological differ-
entiation of gastric cancer, we subdivided gastric cancer
group and calculated positive rates of 4 serum tumorudy subjects







1 (0.8) χ2=4.838, P=0.054
0 (0.0) χ2=38.088, P=0.000
1 (0.8) χ2=18.934, P=0.000
0 (0.0) χ2=37.840, P=0.000
2 (1.6) χ2=74.443, P=0.000
Table 2 Positive rates of 4 tumor markers with single and combined detection in gastric cancer with different stages,
location and differentiation
Cases Positive cases (%)
AFP CEA CA125 CA19-9 Qualitative combined
Stage
early stage 30 1 (3.3) 0 (0.0) 2 (6.7) 2 (6.7) 4 (13.3)
advanced stage 119 6 (5.0) 26 (21.8) 19 (16.0) 29 (24.4) 56 (47.1)
χ2 0.156 7.940 1.711 4.557 11.330
P 1.000 0.005 0.249 0.042 0.001
Location
cardia 13 2 (15.4) 5 (38.5) 1 (7.7) 6 (46.2) 9 (69.2)
gastric body 61 0 (0.0) 12 (19.7) 10 (16.4) 7 (11.5) 21 (34.4)
gastric antrum 70 5 (7.1) 9 (12.9) 10 (14.3) 18 (25.7) 30 (42.9)
multi-site 5 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
χ2 7.504 6.275 1.529 10.630 8.965
P 0.056 0.098 0.696 0.016 0.026
Differentiation
high 6 1 (16.7) 1 (16.7) 1 (16.7) 2 (33.3) 3 (50.0)
moderate 72 4 (5.6) 12 (16.7) 8 (11.1) 13 (18.1) 28 (38.9)
poor 71 2 (2.8) 13 (18.3) 12 (16.9) 16 (22.5) 29 (40.8)
χ2 2.599 0.070 1.024 1.031 0.303
P 0.268 0.930 0.735 0.605 0.839
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showed that the positive rate of serum tumor markers in
the advanced gastric cancer was higher than that in the
early gastric cancer. The positive rate of AFP, CEA and
CA19-9 with combined detection in the cardia cancer
was higher than that in the other parts. However, there
were no significant differences in the positive rate of
serum tumor markers among gastric cancer with differ-
ent differentiation (Table 2).
The association of serum tumor marker levels with the
risk of gastric cancer
To evaluate the significance of serum tumor marker
levels for the diagnosis of gastric cancer, we analyzed theTable 3 The crude odds ratio (OR) and adjusted odds ratio (O
gastric cancer
Indicators Crude odds ratio(OR) P
AFP (ng/mL) 1.005 (0.991~1.019) 0.5
CEA (ng/mL) 1.460 (1.243~1.715) 0.0
CA125 (U/mL) 1.023 (1.010~1.036) 0.0
CA19-9 (U/mL) 1.029 (1.014~1.045) 0.0
combination 509.54 (90.92~2855.78) 0.0
* Adjustment for age and gender.association of serum tumor marker levels with gastric
cancer in gastric cancer group. We got crude odds ratio
(OR) after logistic regression analysis (Table 3). To
exclude the possible effects of age and gender, we got
adjusted odds ratio (ORa) after the adjustment of gender
and age, and the results showed that CEA, CA125 and
CA19-9 levels were positively correlated with the risk of
gastric cancer (Table 3).
Use of normal cut-off values of serum tumor markers for
the diagnosis of gastric cancer
We took the normal value of tumor marker serum level
as cut-off value to determine the negative or positive of
gastric cancer. The results showed that the use of singleRa) between serum tumor marker levels and the risk of
Adjusted odds ratio (ORa)* P
17 1.001 (0.987~1.015) 0.872
00 1.389 (1.184~1.630) 0.000
01 1.020 (1.006~1.034) 0.005
00 1.026 (1.010~1.041) 0.001
00 341.87 (61.19~1910.10) 0.000
Table 4 Use of normal cut-off values of serum tumor markers for gastric cancer diagnosis
AFP CEA CA125 CA19-9 Combination
Normal boundary value ≤7 ng/mL ≤6.5 ng/mL ≤35 U/mL ≤27 U/mL -
AUC (95% CI) 0.519 0.583 0.553 0.585 0.667
(0.459~ (0.523~ (0.493~ (0.525~ (0.609~0.726)
0.579) 0.643) 0.614) 0.645)
Sensitivity (%) 4.7 17.4 14.1 20.8 40.3
Specificity (%) 99.1 99.1 96.6 96.2 93.2
Accuracy (%) 62.5 67.4 64.6 66.9 72.7
Positive/Negative predictive value (%) 77.8/62.1 92.9/65.4 72.4/63.9 77.5/65.7 78.9/71.1
Positive/negative likelihood ratio 5.52/0.96 20.5/0.83 4.14/0.89 5.43/0.82 5.91/0.64
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but poor sensitivity (4.7%-20.8%) for the diagnosis of
gastric cancer (Table 4). The sensitivity was improved
with the combined use of serum tumor markers, but
was still low (Table 4).
Use of optimum cut-off values of serum tumor markers
for the diagnosis of gastric cancer
Since the sensitivity in gastric cancer diagnosis with the
use of normal cut-off values of four serum tumor
markers was low, the potential in clinical application
would be limited. Therefore, we analyzed the serum
markers to obtain AUC of ROC curve, determined
optimum diagnostic cut-off values, and then calculated
their diagnostic values on gastric cancer. The results
showed that the use of optimum boundary values could
significantly improve the sensitivity in gastric cancer
diagnosis with CEA and combination (58.4% and 47.7%,
respectively) (Table 5).
Discussion
In this study we analyzed the diagnostic value of four
common clinical serum tumor markers AFP, CEA,
CA125 and CA19-9 for gastric cancer. We compared
the serum levels of these four markers in the gastric
cancer group, benign gastric disease group and healthyTable 5 Use of optimal boundary values of serum tumor mar
AFP CEA
AUC (95% CI) 0.449 0.767
(0.390~ (0.718~
0.509) 0.816)
Positive boundary value ≥7.29 ng/mL ≥2.24 n
Sensitivity (%) 4.7 58.4
Specificity (%) 99.1 83.4
Accuracy (%) 62.5 73.7
Positive/negative predictive value (%) 77.8/62.1 69.0/76.
Positive/Negative likelihood ratio 5.52/0.96 3.52/0.5control group, and found that the serum levels of all
four markers were higher in gastric cancer group than in
the benign gastric disease group and the healthy control
group. Especially, the serum levels of CEA, CA125 and
CA19-9 were significantly higher than in the benign
gastric disease group and the healthy control group
(P <0.005). In contrast, the serum levels of these four
markers were not significantly different between the
benign disease group and healthy control group (P =
0.581-0.844). These data suggest that these markers have
diagnostic value for gastric cancer.
When we took the normal values of four markers as
cut-off value to determine the negative or positive of
the clinical specimens, we found that the specificity of
four markers in the diagnosis of gastric cancer was
more than 95%, when used individually, but the sensi-
tivity was very low, ranging from 4.7% to 20.8%, and
AUC was no more than 0.6. Thus single marker for
clinical gastric cancer diagnosis is very limited [8].
When the four markers were combined, the sensitivity
of the diagnosis of gastric cancer reached 40.3%, but
was still not ideal.
To improve the sensitivity of gastric cancer diagnosis,
we performed logistic regression analysis and used ROC
curve to determine the optimum cut-off values. With









0 74.4/65.2 72.6/67.7 77.2/73.3
0 4.57/0.84 4.18/0.75 5.33/0.58
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ficity was decreased from 99.1% to 83.4%), and AUC
reached 0.767. These results are consistent with earlier
studies performed in Chinese population [5,9].
Furthermore, we investigated the relationship between
serum levels of tumor markers and clinicopathological
features of gastric cancer. We found that the positive
rates of CEA, CA19-9, and combined use of four
markers were higher in the advanced gastric cancer than
in the early gastric cancer. The positive rates of CA19-9
and combined use of four markers were higher in the
cardia cancer than in the other parts of the gastric
cancer. Our results are in agreement with previous
reports that the stage and sites of gastric cancer would
affect serum marker levels [10-12]. However, the positive
rates of markers among the gastric cancer with different
differentiation were not statistically significant, suggesting
that the differentiation has little impact on gastric
carcinoma marker level as reported previously [13].
In this study, the age and gender ratio of study sub-
jects in the three groups were statistically significant. To
avoid the possible bias caused by these factors, we
analyzed the effects of age and gender on serum levels
of the four markers in the diagnosis of gastric cancer.
We performed multivariate logistic regression analysis
and got ORa adjusted for age and gender. The results
showed that the differences in age and gender could not
change the diagnostic value of markers for gastric
cancer.Conclusions
While the four common tumor markers when used indi-
vidually has little clinical value in the diagnosis of gastric
cancer, with the help of the ROC curve analysis and
logistic regression analysis, we could determine the
optimal cut-off values of the markers and improve the
diagnosis of gastric cancer based on these markers. These
results suggest that the optimal application of these
common tumor markers could promote the clinical
screening and diagnosis of gastric cancer.
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